BioCentury
ARTICLE | Company News

Athersys, Healios deal

February 1, 2016 8:00 AM UTC

Athersys granted Healios exclusive Japanese rights to develop and commercialize MultiStem to treat ischemic stroke. Healios also has an exclusive option to develop and commercialize the product for two additional indications in Japan, including acute respiratory distress syndrome (ARDS) and another orthopedic indication. Healios also gains an exclusive license to use Athersys technology to develop and commercialize Healios’ “organ bud” technology, initially for transplantation to treat liver disease or dysfunction, which may be expanded upon exercise of the option.

Athersys will receive a $15 million license fee and is eligible for up to $30 million in development and regulatory milestones and up to $185 million in sales milestones for the stroke indication, plus tiered double-digit royalties increasing into the high teens. If Healios expands the MultiStem deal to include the additional indications, Athersys will receive a $10 million license expansion fee and be eligible for additional milestones. ...